Xcelience, Penn Pharma Form Joint Venture
July 12, 2010
Xcelience LLc will expand its pharmaceutical manufacturing to Europe as part of a joint venture agreement with Penn Pharma, reports Bizjournal.com. The joint venture provides pharmaceutical and biotechnology companies a chance to manufacture potential drugs used in clinical trials faster and closer to clinical sites, a release said. Xcelience, a contract research organization, uses Xcelodose to manufacture small doses of drugs in development at its corporate headquarters in Tampa. Xcelodose is a capsugel technology system that allows companies to fill capsules with drug substances alone, which shortens the drug development process. Capsugel is a division of Pfizer Inc. Under the joint venture, Xcelience will work with Penn Pharma on Xcelodose technology at Penn Pharma’s office in South Wales, closer to the clinical sites used by pharma and biotech firms that are doing trials in Europe. Penn Pharma provides pharmaceutical development and custom manufacturing services to the international health care industry. Xcelience provides formulation development, preformulation, analytical and clinical trial manufacturing.